GLA
FOLD

Great Lakes Advisors’s Amicus Therapeutics FOLD Stock Holding History

Great Lakes Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-178,477
Closed -$1.68M – 820
2024
Q4 		$1.68M Sell
178,477
-46,132
-21% -$480K 0.01% 500
2024
Q3 		$2.4M Sell
224,609
-241
-0.1% -$2.63K 0.02% 455
2024
Q2 		$2.23M Sell
224,850
-552
-0.2% -$5.67K 0.02% 455
2024
Q1 		$2.66M Buy
225,402
+81,150
+56% +$1.04M 0.02% 436
2023
Q4 		$2.05M Sell
144,252
-40,132
-22% -$456K 0.02% 456
2023
Q3 		$2.24M Sell
184,384
-173,202
-48% -$2.23M 0.02% 444
2023
Q2 		$4.49M Sell
357,586
-216,220
-38% -$2.57M 0.04% 346
2023
Q1 		$6.36M Buy
+573,806
New +$7.07M 0.06% 309

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Great Lakes Advisors's FOLD Position: Q1 2025 in Review

Great Lakes Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 178,477 shares — an estimated $1.68M sold.

Great Lakes Advisors first reported a position in FOLD in Q1 2023 and held it in 8 quarters. The position peaked at $6.36M in Q1 2023. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Great Lakes Advisors reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Great Lakes Advisors sold 178,477 Amicus Therapeutics shares in Q1 2025, an estimated $1.68M.
  • Great Lakes Advisors first reported a position in Amicus Therapeutics in Q1 2023 and held it in 8 quarters.
  • Great Lakes Advisors's Amicus Therapeutics position peaked at $6.36M in Q1 2023.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Great Lakes Advisors's 13F filing for Q1 2025, filed 16 May 2025.